April 7, 2017

Focus on Clay Siegall’s Efforts to Bolster Cancer Therapy

Written by

A large number of companies are making great strides in cancer research, and Seattle Genetics is one of the most interesting of all the companies that have been around for the past decade. Clay Siegall, the CEO of Seattle Genetics has spoken of the great innovations his company is focusing on as it seeks to make more advancement in the field of cancer therapy. Seattle Genetics’ stock price has continued soaring and has managed to triple in a period of five years. This is a clear indication that the company is onto something significant in its field.

Passion to Improve the Lives of Cancer Patients

Siegall in his current position as the CEO of Seattle Genetics remains passionate in his quest to improve the lives of patients affected by cancer. He also serves as the president and board chairman of Seattle Genetics. He has been the CEO from 2002 and has been working tirelessly in the company for over two decades since co-founding it in 1998. He has led the company to immense advancements in the field of cancer research as well as ground-breaking therapies to assist cancer patients.

Education and Early Work History

After getting his Ph.D. in Genetics from the George Washington University, he has managed to achieve a number of proficient accomplishments. He started his research career at Bristol-Myers Squibb Pharmaceutical Research Institute as a senior research investigator. He then became the principal scientist before moving to the National Cancer Institute as a staff and biotechnology fellow. After his professional advancement he helped in launching Seattle Genetics. Dr. Siegall’s achievements are a testimony of his commitment to concentrate on the most imperative research and being thorough in implementing avant-garde research advancements. He has a true desire to assist patients and is motivated to help end their suffering.

About Clay Siegall

Clay Siegall is a trained scientist with a focus on target cancer therapies. He has led Seattle Genetics in the development of antibody-drug conjugates (ADCs) and securing FDA’s approval of the first ADC product, ADCETRIS (brentuximab vedotin) in 2011. Seattle Genetics is in the process of advancing a varied conduit of proprietary ADCs to be used in cancer treatment. Dr. Siegall has worked hard to secure over $1.2 billion in financing from both public and private companies.


Category : ADCETRIS

Leave a Reply

Your email address will not be published. Required fields are marked *

Proudly powered by WordPress and Sweet Tech Theme